Roche says it has received CE marking for its AI-based Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution, which provides critical predictions for adults with type 1 and type 2 diabetes on flexible insulin therapy.

"Built-in AI-trained algorithms will enable users to proactively intervene when their blood glucose levels require attention and even before a complication occurs," explains the Swiss healthcare group.

The Accu-Chek SmartGuide CGM solution provides 14 days of accurate real-time blood glucose values for diabetic patients. It is due to be launched in selected European markets in the coming months.

Copyright (c) 2024 CercleFinance.com. All rights reserved.